drugset / Trial / NCT05474378
B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme
Phase 1
Recruiting
39 enrolled
Stanford University
California Institute for Regenerative Medicine (CIRM) · collabParker Institute for Cancer Immunotherapy · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open label, non-randomized, single site Phase I study to test the manufacturing feasibility and safety of locoregional (LR) administration of B7-H3CART into the central nervous system of adult subjects with recurrent IDH wild-type GBM using a standard 3+3 dose escalation design.
Timeline
- Start
- 2022-07-12
- Primary completion
- 2026-08
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | B7-H3CART | Cell therapy | 5e+06 cells | Other |
| Subject | B7-H3CART | Cell therapy | 1e+07 cells | Other |
| Subject | B7-H3CART | Cell therapy | 2.5e+07 cells | Other |
| Subject | B7-H3CART | Cell therapy | 5e+07 cells | Other |
| Subject | B7-H3CART | Cell therapy | 1e+08 cells | Other |